clinical trial · NCT01714843
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Constipation-predominant Irritable Bowel Syndrome (IBS-C)linaclotideplacebo
brief summary
This study is to investigate the efficacy, safety, and plasma concentration change of ASP0456 in patients with constipation-predominant irritable bowel syndrome.
started
Aug 10, 2012
primary completion
Dec 7, 2013
completion
Dec 7, 2013
last updated
Oct 18, 2024
detailed description
This study is a multicenter, double-blind, placebo-controlled, parallel-group, comparative study to investigate dose-responses of efficacy, safety, and pharmacokinetics of ASP0456 in patients with constipation-predominant irritable bowel syndrome (IBS-C) according to the Rome III Diagnostic Criteria (2006 revised edition, established by the Rome III Committee) after oral administration of ASP0456.
official title
Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Constipation-predominant Irritable Bowel Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol